PharmaMar Employee Directory
Biotechnology ResearchCommunity of Madrid, Spain501-1000 Employees
PharmaMar is a mid-sized biopharmaceutical company focused on oncology, pursuing cancer therapies inspired by marine-derived compounds. Headquartered in Madrid, it operates with subsidiaries across several European countries and the United States, and it wholly owns Sylentis, a unit dedicated to gene-silencing research. The company maintains an active pipeline and R&D program in oncology, with Yondelis available in Europe and additional clinical-stage candidates such as lurbinectedin, PM14, PM534 and PM54 advancing in development. Its market serves healthcare professionals seeking new cancer treatments and patients who may benefit from innovative therapies, with current commercial activity centered in Europe and ongoing work on solid-tumor indications. In February 2026, PharmaMar announced a collaboration with Globant SA to explore the use of artificial intelligence to aid cancer drug discovery.